Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is delighted to announce that its CEO, Dr. Roger McIntyre, has been selected to be a keynote speaker at the Wonderland: Miami conference.
The two-day event, which is scheduled to begin Mon., Nov. 8 at the Adrienne Arsht Center for the Performing Arts of Miami-Dade County, will act as a launching pad for innovative companies connected to the psychedelic medicine space.
Dr. McIntyre will discuss the challenges patients with medication-resistant mental health issues face in accessing ketamine and other psychedelic therapies as well as developing new therapies. He will also outline best practices for clinicians according to the international guidelines developed by him and other members of Braxia Scientific’s leadership, as published in the American Journal of Psychiatry. This presentation will take place Mon., Nov. 8, at 1 p.m. ET.
As a world-leading depression researcher, Dr. McIntyre has been named one of the world’s most influential scientific minds by Clarivate for seven consecutive years. He is a professor of Psychiatry and Pharmacology at the University of Toronto and holds professorships at universities in the United States and Asia, including the University of California Riverside School of Medicine, State University of New York (SUNY), Upstate Medical University in Syracuse, N.Y., Guangzhou Medical University, and the College of Medicine at Korea University. He is also the founder of the Canadian Rapid Treatment Center of Excellence, a wholly owned Braxia subsidiary that operates a network of ketamine clinics treating depression and other mental health disorders.
About Braxia Scientific Corp.
Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.